← Leaderboards
Silvia C Formenti
New York University School Of Medicine
$2,888,589
Attributed
$3,732,909
Total exposure
16
Grants
13
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2M · FY2005–25$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$9,866,503 · 17
By mechanism
U54$7,187,781 · 3
R01$1,843,733 · 2
S10$469,716 · 1
M01$252,462 · 10
P30$112,811 · 1
Top collaborators
- Sylvia Adams5 shared
- Joseph O Deasy5 shared
- Ralph R Weichselbaum5 shared
Most similar at New York University School Of Medicine
Same institution · by research overlap
- Lorna Thorpe$21,064,292
- Jonathan Melamed$2,363,631
- John A Dodson$11,071,981
- Sylvia Adams$1,535,260
- John Ross Rizzo$2,213,516
Others in their field
Top investigators on “Tumor”
- David Heimbrook · Leidos Biomedical Research, Inc.$636,492,067
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Gregory H Reaman · National Childhood Cancer Foundation$208,276,509
- Richard K. Wilson · Washington University$203,917,615
- Norman Wolmark · Nsabp Foundation, Inc.$177,323,696
- Ronald T Mitsuyasu · University Of California Los Angeles$138,361,819
Research focus
TumorRadiation TherapyRadiationClinical TrialsMalignant NeoplasmsMolecularImmunityImmune ResponseFundingImmuneRadiobiologyInstitutionScientistCollaborationsTissuesIonizing RadiationResearch PersonnelResponseRadiation OncologyChemotherapyGrantRadiation EffectBaseBiopsy
Grant awards (33)
Dynamics of Immune Response in Irradiated Rectal Cancer$1,275,371
U54 · FY2025 · CA · contact PI
Administrative Core$218,723
U54 · FY2025 · CA · contact PI
Dynamics of Immune Response in Irradiated Rectal Cancer$1,423,932
U54 · FY2024 · CA · contact PI
Administrative Core$351,638
U54 · FY2024 · CA · contact PI
A Digital Twin for rectal cancer to guide adaptive radiotherapy$246,001
U54 · FY2024 · CA · contact PI
Dynamics of Immune Response in Irradiated Rectal Cancer$1,477,107
U54 · FY2023 · CA · contact PI
Administrative Core$343,328
U54 · FY2023 · CA · contact PI
Dynamics of Immune Response in Irradiated Rectal Cancer$1,711,183
U54 · FY2022 · CA · contact PI
PSMA/MR-guided Stereotactic Body Radiotherapy for High Risk Prostate Cancer$155,093
R01 · FY2022 · CA · contact PI
Administrative Core$140,498
U54 · FY2022 · CA · contact PI
Immunomodulation of breast cancer via TLR7 agonist imiquimod and radiotherapy.$373,301
R01 · FY2015 · CA · contact PI
Immunomodulation of breast cancer via TLR7 agonist imiquimod and radiotherapy.$206,156
R01 · FY2014 · CA · contact PI
Immunomodulation of breast cancer via TLR7 agonist imiquimod and radiotherapy.$353,046
R01 · FY2013 · CA · contact PI
Immunomodulation of breast cancer via TLR7 agonist imiquimod and radiotherapy.$377,228
R01 · FY2012 · CA · contact PI
Breast Cancer$27,413
P30 · FY2012 · CA · contact PI
Immunomodulation of breast cancer via TLR7 agonist imiquimod and radiotherapy.$378,909
R01 · FY2011 · CA · contact PI
Breast Cancer$22,676
P30 · FY2011 · CA · contact PI
GammabeamX200 Preclinical Research Irradiator$469,716
S10 · FY2010 · RR · contact PI
Breast Cancer$23,869
P30 · FY2010 · CA · contact PI
Breast Cancer$24,770
P30 · FY2009 · CA · contact PI
RESPONSE, RESISTANCE AND METASTASIS OF LOCALLY-ADVANCED BREAST CANCER (LABC)$15,300
M01 · FY2008 · RR · contact PI
Breast Cancer$14,083
P30 · FY2008 · CA · contact PI
CLINICAL TRIAL: INDIVIDUALIZED TX OF BREAST CANCER BASED ON TUMOR MOLECULAR CHAR$2,166
M01 · FY2008 · RR · contact PI
INDIVIDUALIZED TX OF BREAST CANCER BASED ON TUMOR MOLECULAR CHARACTERISTICS$61,938
M01 · FY2007 · RR · contact PI
RESPONSE, RESISTANCE AND METASTASIS OF LOCALLY-ADVANCED BREAST CANCER (LABC)$14,597
M01 · FY2007 · RR · contact PI
BI-WEEKLY TAXOL & RT IN ANDROGEN ABLATED ADVANCED PROSTATE CANCER$10,258
M01 · FY2007 · RR · contact PI
INDIVIDUALIZED TX OF BREAST CANCER BASED ON TUMOR MOLECULAR CHARACTERISTICS$20,576
M01 · FY2006 · RR · contact PI
BI-WEEKLY TAXOL & RT IN ANDROGEN ABLATED ADVANCED PROSTATE CANCER$5,144
M01 · FY2006 · RR · contact PI
INDIVIDUALIZED TX OF BREAST CANCER BASED ON TUMOR MOLECULAR CHARACTERISTICS$24,827
M01 · FY2005 · RR
BI-WEEKLY TAXOL &RT IN ANDROGEN ABLATED ADVANCED PROSTATE CANCER$23,395
M01 · FY2005 · RR
PHASE I: RT + PACLITAXEL PLUS DOSE ESCALATION OF CARBOPLATIN IN CERVICAL CANCER$9,071
M01 · FY2005 · RR
Individualized Tx of Breast Cancer Based on Tumor Molecular Characteristics$51,319
M01 · FY2004 · RR
Phase I: RT + Paclitaxel plus Dose Escalation of Carboplatin in Cervical Cancer$13,871
M01 · FY2004 · RR